Autolus Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 470

Employees

  • Stock Symbol
  • AUTL

Stock Symbol

  • Share Price
  • $6.23
  • (As of Friday Closing)

Autolus General Information

Description

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Contact Information

Website
www.autolus.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NAS
Corporate Office
  • The Mediaworks, 191 Wood Lane
  • White City
  • London W12 7FP
  • England, United Kingdom
+44 020 0000 0000

Autolus Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Autolus Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.23 $6.00 $1.61 - $7.45 $1.45B 232M 1.65M -$0.98

Autolus Financials Summary

In Thousands,
USD
TTM 30-Sep-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 148,114 180,885 227,200 342,726
Revenue 5,523 6,194 1,507 242
EBITDA (162,745) (158,586) (156,687) (161,135)
Net Income (158,163) (148,839) (142,096) (142,094)
Total Assets 406,098 490,274 405,560 294,237
Total Debt 52,458 24,256 20,998 54,161
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Autolus Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Autolus‘s full profile, request access.

Request a free trial

Autolus Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the t
Biotechnology
London, United Kingdom
470 As of 2023
00.000
00000000 00.000

000000

eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt i
000000000000000
Foster City, CA
00000 As of 0000
000.00
000000000 000.00

000000

labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitati
0000000000000
Illkirch-Graffenstaden, France
000 As of 0000
00000
0000 0000-00-00
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Autolus Competitors (20)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gilead Sciences Formerly VC-backed Foster City, CA 00000 000.00 000000000 000.00
Transgene Corporation Illkirch-Graffenstaden, France 000 00000 000000000 00000
Immatics Formerly VC-backed Tuebingen, Germany 000 00000 00000000 00000
Arcus Biosciences Formerly VC-backed Hayward, CA 000 00.000 000000000 00.000
Seagen Formerly VC-backed Bothell, WA 0000 00.000 000000&0 00.000
You’re viewing 5 of 20 competitors. Get the full list »

Autolus Patents

Autolus Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202318794-D0 Cd19car t-cell treatment of relapsed/refractory b-cell acute lymphoblastic leukaemia Pending 08-Dec-2023
GB-202316745-D0 Cd19car t-cell treatment of relapsed/regractory b-cell acute lymphoblastic leukaemia Pending 01-Nov-2023
GB-202316183-D0 Products and methods for treating autoimmune diseases Pending 23-Oct-2023
GB-202316184-D0 Method Pending 23-Oct-2023
GB-202312009-D0 Methods and cell compositions Pending 04-Aug-2023
To view Autolus’s complete patent history, request access »

Autolus Executive Team (19)

Name Title Board Seat Contact Info
Christian Itin Ph.D Chief Executive Officer & Board Member
Lucinda Crabtree Ph.D Chief Financial Officer, Finance & Senior Vice President
Robert Dolski Chief Financial Officer
Christopher Vann Chief Operating Officer & Senior Vice President
David Brochu Chief Technology Officer, Technology & Senior Vice President
You’re viewing 5 of 19 executive team members. Get the full list »

Autolus Board Members (12)

Name Representing Role Since
Christian Itin Ph.D Autolus Chief Executive Officer & Board Member 000 0000
Cynthia Butitta Autolus Board Member 000 0000
Elisabeth Leiderman MD Self Board Member 000 0000
John Berriman Self Board Member 000 0000
John Johnson Self Chairman of Board of Directors 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Autolus Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Autolus Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Autolus‘s full profile, request access.

Request a free trial

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »